AFM11 – Non-Hodgkin’s Lymphoma
Affimed´s program AFM11 provides a novel therapeutic approach for the treatment of Non-Hodgkin Disease.
AFM11 – Non-Hodgkin Lymphoma
|Compound||Target||Indication||Discovery||Preclinical||Phase I||Phase II|
|blue = current development status - green = planned development|
|AFM11||CD19xCD3||Non-Hodgkin Lymphoma||100% completed||80 % 100%||100%|
The TandAb® AFM11 is specifically designed to treat Non-Hodgkin Lymphoma. AFM11 is a RECRUIT-TandAb® targeting CD19 and CD3. AFM11 shows highly specific and effective engagement of T-cells, inducing fast and strong tumor cell killing.
AFM11 has shown very convincing in vivo results and a benign safety profile. The product is well expressed in CHO cells (g/L) and is highly stable. AFM11, currently in late stage preclinical development and GMP manufacturing, is due to enter clinical trials in 2013.
Non Hodgkin Lymphoma
Haematological malignancies, comprising leukemias, lymphomas, multiple myeloma and myeloplastic syndromes account for roughly 15% of all types of cancer. At least 80% of all lymphomas belong to the NHL group and 30% of all new leukemia cases are of the CLL (chronic lymphatic leukemia) type. Therefore, considering all B-cell lymphoma NHL and CLL subtypes, the total annual incidence in the seven major markets is at least 121,800 cases, forecasted to increase slightly during the next ten years. Current treatments of NHL are in many cases, especially for nonresponding or relapsing patients, not effective enough to increase the patient’s quality of life significantly. The situation is even worse for patients suffering with CLL. This type of leukemia remains incurable when using current treatment options.
AFM11 is developed specifically against the CD19 tumor target antigen, which is even more widely expressed on malignant B-lymphocytes than CD20 (used as a target in current therapeutics). Using T-cells as very strong and potent immune effector cells, AFM11 will represent a unique immune targeted therapeutic product with high efficacy and safety.
Besides the high medical need, the market for hematological malignancies will amount to a total of US$ 3.5 billion in 2018, offering a huge but competitive environment for all new R&D pipeline products.